Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The emerging role of real-world data in oncology care in Japan
H Bando, E Tajima, Y Aoyagi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 26, 2013
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
Y Yamada, N Boku, T Nishina, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
E Van Cutsem, K Muro, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2016
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
M Kanai, T Kawaguchi, M Kotaka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K Yamazaki, T Yamanaka, M Shiozawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2021
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
M Kanai, T Kawaguchi, M Kotaka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
S-E Al-Batran, E Van Cutsem, S C Oh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D Arnold, C S Fuchs, J Tabernero, et al.
Annals of Human Genetics
|
August 16, 2006
Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences
K Sai, M Itoda, Y Saito, et al.
The Pharmacogenomics Journal
|
November 30, 2005
Haplotype structures of the UGT1A gene complex in a Japanese population
M Saeki, Y Saito, H Jinno, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The emerging role of real-world data in oncology care in Japan
H Bando, E Tajima, Y Aoyagi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 26, 2013
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
Y Yamada, N Boku, T Nishina, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
E Van Cutsem, K Muro, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2016
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
M Kanai, T Kawaguchi, M Kotaka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K Yamazaki, T Yamanaka, M Shiozawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2021
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
M Kanai, T Kawaguchi, M Kotaka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
S-E Al-Batran, E Van Cutsem, S C Oh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D Arnold, C S Fuchs, J Tabernero, et al.
Annals of Human Genetics
|
August 16, 2006
Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences
K Sai, M Itoda, Y Saito, et al.
The Pharmacogenomics Journal
|
November 30, 2005
Haplotype structures of the UGT1A gene complex in a Japanese population
M Saeki, Y Saito, H Jinno, et al.
Page
of 11